resistanceBio has filed a notice of an exempt offering of securities to raise $12,776,288.00 in New Equity and Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, resistanceBio is raising up to $12,776,288.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kyle Lapham played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About resistanceBio
Helping patients fight treatment-resistant cancer. resistanceBio can discover and overcome clinical treatment resistance pre-clinically. resistanceBio is the first platform that generates real resistance data to solve drug resistance. resistanceBio’s platform was used to preclinically identify drug resistance mechanisms to a KRAS inhibitor in colorectal cancer. resistanceBio’s model identified on target mutations and off target resistance mechanisms found in clinical trials.
To learn more about resistanceBio, visit http://www.resistance.bio/
Contact:
Kyle Lapham, Chief Executive Officer
925-708-6165
https://www.linkedin.com/in/kylelapham/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.